Sun Pharmaceutical Industries Ltd. Latest Updates

Financial Results Sun Pharmaceutical Industries Ltd. reported its financial results for the first quarter of fiscal year 2025-26. The company saw its net profit grow by over 9% year-on-year, reaching ₹3,096.63 crore. This represents a 23.3% increase compared to the previous quarter. The company's financial performance was driven by strong sales volumes and operational efficiency. Corporate Actions and Product Developments Sun Pharma recently completed its acquisition of Checkpoint Therapeutics, a US-based oncology company. This acquisition adds UNLOXCYT™, an FDA-approved treatment for a type of advanced skin cancer, to Sun Pharma's portfolio and strengthens its position in the onco-dermatology space. The company has also launched a new product, LEQSELVI™ (deuruxolitinib), in the United States for the treatment of severe alopecia areata. This new drug is a significant addition to its specialty portfolio. Regulatory and Other Updates Sun Pharma's US subsidiary recently initiated a Class II recall of some of its products from the US market due to a manufacturing issue involving a foreign substance. In a separate corporate development, the company's Board of Directors approved quarterly financial results and made changes to the composition of its board committees.